Visikol is a contract research services company that is focused on accelerating the drug discovery and development process through providing its clients with advanced tissue imaging and advanced cell culture services. Today, Visikol counts all twenty of the top twenty pharmaceutical companies as clients and has been instrumental in dozens of drug discovery programs. The company provides end-to-end services that include 3D tissue imaging, multiplex tissue imaging, digital pathology, high content imaging, 2D cell culture assays, 3D cell culture assays and ex vivo tissue slice assays. Visikol’s expertise lies in both transforming tissues into actionable insights as well as bridging the gap between in vitro assays and in vivo results through the use of best-in-class cell culture models. In addition to its services, Visikol sells a suite of tissue clearing reagents and kits as well as the HUREL® Micro Liver portfolio of primary hepatocyte liver models.
Looking for a particular Visikol employee's phone or email?
The Visikol annual revenue was $8.6 million in 2026.
Alex Armento is the CEO of Visikol.
15 people are employed at Visikol.
Visikol is based in Hampton, New Jersey.
The NAICS codes for Visikol are [541, 54171, 54, 5417, 541714].
The SIC codes for Visikol are [87, 873].